Over the past decade, gene and cell therapy has gone from a clinical concept to a mainstream reality. In 2017 the U.S. Food and Drug Administration (FDA) approved its first gene therapy, and the market has continued to expand.

Gene and cell therapy organizations are asked to balance the need for rapid clinical progression and stringent quality expectations throughout development. In this document, Aldevron provides an in-depth look at preparing for plasmid manufacturing based on our years of experience. Get your free whitepaper copy today.